临床试验透明化与编辑伦理-中国期刊协会医药卫生期刊分会医学编辑.PDF

临床试验透明化与编辑伦理 Clinical trial transparence and publication ethics: challenges and development 吴泰相 Wu Taixiang 中国临床试验注册中心 Chinese Clinical Trial Registry 2013年6月1 日北京 我国医学期刊面临的挑战 Challenges we are facing • 例： – 电话通知某杂志编辑部邀请参加编辑伦理学研 讨会，被拒绝，理由 We telephoned a chief-editor to invite him to attend the publication ethics conference, but we was rejected: • 我们杂志过得好得很，稿源不愁，办刊经费不愁， 发行不耽心，没必要搞什么编辑伦理学 Our journal alive very comfortable with rich manuscript resource, rich income and never worry about the publication pathway, why to talking about publication ethics? 挑战是什么？？？ What is the real challenge? 缺稿源? Lack of manuscript resource? 进不了SCI? 发行? Not been Publication included in SCI? market? 真正的挑战 Real challenges • 进SCI是必须的吗？ • Is that necessary to be included in SCI? – “杞人忧天” – “No, don’t worry about it. It does not falls down. – 自给自足，丰衣足食 – We can support ourselves 稿源？Manuscript resource? • 中国医疗卫生从业者200多万 ，职称文章 需求市场巨大 There are more than two million medical staffs, it’s a huge market of publishing papers for promoting position – 冷笑话： • 某主编在某专业学会上发言：“我们也要认真积极 地狠抓办刊质量，满足广大医务工作者的需要，争 取把拒稿率从20%降到10%” 发行？Distribution channel? • 中国1700多种医学期刊，还有增多趋势 • There are more than 1700 medical journals in China • 问题：有多少种是因发行渠道的问题而停 刊？ • How many journals was closed due to distribution channel problem?